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Abstract
The COMBINE Study sought to answer questions about the benefits of combining behavioral and
pharmacological interventions (naltrexone and acamprosate) in alcohol-dependent patients. Our
goals were to identify trajectories of heavy drinking prior to randomization in COMBINE, to
characterize subjects in these trajectories, and to assess whether pre-randomization trajectories
predict drinking outcomes. We analyzed daily indicators of heavy drinking in 90 days prior to
randomization using a trajectory-based approach. Each subject was assigned to the most-likely
pre-randomization heavy drinking trajectory, and the baseline characteristics of participants in the
baseline trajectories were compared. Main and interactive effects of these trajectories and
treatment factors (acamprosate, naltrexone or CBI) on summary drinking measures during active
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treatment (16 weeks) were assessed. We identified five trajectories of heavy drinking pre-
randomization: “T1: frequent heavy drinkers”, “T2: very frequent heavy drinkers”, “T3: nearly
daily heavy drinkers”, “T4: daily heavy drinkers” and “T5: daily heavy drinkers stopping early”
prior to randomization. Trajectory membership was significantly associated with all drinking
outcomes. Subjects in “T5: daily heavy drinkers stopping early” had comparable drinking
outcomes to the subjects in “T1: frequent heavy drinkers” while the remaining trajectories were
associated with significantly worse outcomes. Baseline trajectory did not interact significantly
with treatment condition. These exploratory analyses confirmed the hypothesis that baseline
trajectories predict post-randomization drinking outcomes. Interestingly, “T5: daily heavy drinkers
stopping early” had outcomes that were comparable to the least severe baseline trajectory “T1:
frequent heavy drinkers” and baseline trajectories of heavy drinking did not moderate treatment
effects.
Keywords
trajectory-based analysis; clinical trial; baseline predictors; naltrexone; acamprosate; combined
behavioral intervention
Introduction
The COMBINE study was designed to assess the effects of naltrexone, acamprosate and
Combined Behavioral Intervention (CBI) in alcohol-dependent patients. The original
analyses of the two primary endpoints, time to the first day of heavy drinking and percent
days abstinent, revealed that either naltrexone or CBI without naltrexone improved
outcomes (Anton et al, 2006) but the combination of CBI and naltrexone did not yield better
outcomes than either treatment alone. No significant effects of acamprosate either alone or
in combination were found.
Secondary trajectory-based analyses of pre-randomization any drinking days were
performed to characterize the heterogeneity of participants’ drinking behavior prior to entry
into treatment with the goal of understanding some of the negative findings regarding
acamprosate and the combination of naltrexone and CBI. In these analyses, we
(Gueorguieva et al., 2011) identified five trajectories of any drinking in the 90 days prior to
randomization and assessed predictive and moderating effects of these trajectories on post-
randomization drinking outcomes. We showed that acamprosate appeared beneficial in a
subset of the subjects (very frequent drinkers) and counterproductive in another subset
(consistent daily drinkers who had longer duration of pretreatment abstinence: e.g. ≥ 14
days). Baseline trajectories of any drinking also moderated naltrexone effects such that
naltrexone improved outcome the most for very frequent drinkers. Baseline trajectories of
any drinking did not moderate CBI effects.
Since baseline trajectories of any drinking assess only frequency of drinking and length of
pre-randomization abstinence but not intensity of drinking, the goal of the current study was
to extend the use of the trajectory-based approach to modeling baseline trajectories of heavy
drinking which take these features into account. In our analyses of post-randomization
trajectories of any drinking and heavy drinking in COMBINE (Gueorguieva et al., 2010) we
found different numbers of trajectories for any and heavy drinking (6 for any drinking and 4
for heavy drinking) and differential treatment effects. For any drinking, CBI had a unique
effect on reducing the likelihood of increasing to nearly daily drinking, naltrexone had a
unique effect on decreasing nearly daily drinking, and the combination of naltrexone and
CBI increased the chance of decreasing any drinking. For heavy drinking, each treatment
alone (naltrexone, CBI) and the combination lowered the chance to be in the consistent
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heavy drinkers trajectory but the combination was not better than either treatment alone. In
contrast, in an analysis of data from VA study CSP425 of naltrexone (Gueorguieva et al.,
2007), trajectories of any drinking and heavy drinking and treatment effects on these
trajectories were very similar. Hence it is important to assess both trajectories of any and
heavy drinking and it is likely that baseline trajectories of any and heavy drinking have
different effects on outcomes.
In addition, heavy drinking is an important clinical measure providing further rationale for
examining heavy drinking trajectories. Consensus panels conclude that percent heavy
drinking days should be the primary outcome in alcoholism clinical trials (Allen, 2003) and
the percent with no heavy drinking days (PNHDD) has been recommended as a
dichotomous index of good response (Falk et al., 2010) that is associated with low risk of
alcohol related consequences. Percent heavy drinking days also appears to be sensitive to the
beneficial effects of naltrexone (Pettinatti et al., 2006).
We focused on daily measures of heavy drinking because they allowed us to capture
changes in drinking more sensitively than measures of drinking summarized over longer
time-periods (e.g., a week). While it would be of interest to directly model the number of
drinks per day, these values have extreme distributions that can result in spurious latent
classes (Bauer and Curran, 2003, 2004).
The main goals of the current study were to identify and characterize baseline trajectories of
heavy drinking and to assess predictive and moderating effects of baseline trajectories of
heavy drinking on post-randomization drinking outcomes. We focused on trajectory-based
methods since these methods have proven useful in identifying developmental patterns of
alcohol use (Muthén and Muthén, 2000a, b; Hill et al., 2000; Chassin et al., 2000; Del Boca
et al., 2003; Greenbaum et al. 2004), in increasing power for assessment of treatment effects
in clinical trials (Gueorguieva et al., 2007) and in revealing additional information about the
moderators and potential mechanisms of treatment effects (Gueorguieva et al., 2010,
Witkiewitz et al., 2007). Unlike standard summary outcomes, trajectories of heavy drinking
capture different aspects of drinking: the frequency and the trend of intensive drinking and
thus they can be regarded as composite measures of drinking. They also provide easily
interpretable graphical summaries of patterns over time. The trajectory modeling strategy
allows the data to guide the choice of the number of trajectories that best fit the data and to
determine the shape of each trajectory over time. This approach utilizes all available data on
each subject and can be used to estimate the proportion of the population whose treatment
response corresponds most closely to each trajectory group.
Our a priori hypotheses were that baseline trajectories of heavy drinking will be similar to
trajectories of any drinking with slightly smaller probabilities of membership in the more
severe heavy drinking trajectories than in the corresponding any drinking trajectories. We
also hypothesized that trajectories of heavy drinking days will prove to be an important
predictor of treatment outcome independent of treatment condition since frequency of heavy
drinking that exceeds nonhazardous limits (5 or more for men and 4 or more for women) is
associated with increased risk of alcohol-related consequences (Breslow and Graubard,
2008). Based on our analyses of baseline trajectories of any drinking trajectories we were
interested in testing the hypothesis that a trajectory associated with longer duration of
pretreatment abstinence from heavy drinking will be associated with better outcomes than a
trajectory with similar level of heavy drinking but shorter abstinence.
We expected that both naltrexone and acamprosate would have the strongest impact on
drinkers whose baseline trajectories suggested a pattern of more persistent heavy drinking.
These predictions were based on naltrexone’s most consistent effect which is to reduce the
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frequency of heavy drinking (Pettinati et al., 2006) and acamprosate’s hypothesized effect
on attenuating protracted abstinence effects (De Witte et al., 2003; Heilig and Egli, 2006;
Mann et al., 2008), which might be expected to be greater among more frequent heavy
drinkers. However, motivated by our analyses of trajectories of any drinking, we were also
interested in whether a trajectory of intermediate heavy drinking would be associated with a
beneficial effect of acamprosate and a trajectory of daily heavy drinking with early initiation
of abstinence with poorer outcomes with acamprosate. Since any drinking and heavy
drinking capture different aspects of drinking behavior, we hypothesized that trajectories of
any drinking and heavy drinking may have different effects on outcome. Thus, the current




The COMBINE study enrolled 1,383 subjects with alcohol dependence (Anton et al, 2006).
Subjects were recruited by advertisements and from clinical referrals at 11 US academic
sites between January 2001 and January 2004. Approximately 5000 subjects were screened,
72.1% did not meet eligibility criteria and were excluded, 27.9% (1383, 428 women and 955
men) were randomized. Participants’ median age was 44 years, 71% had at least 12 years of
education, and 42% were married. Ethnic minorities comprised 23% of the sample. Specific
inclusion and exclusion criteria can be found in the main report (Anton et al., 2006). All
subjects were required to have between 4 to 21 days of abstinence; and (3) more than 14
drinks (women) or 21 drinks (men) per week, with at least 2 heavy drinking days (defined as
4 or more drinks per day for women and 5 or more drinks per day for men) during a
consecutive 30-day period within the 90 days prior to baseline evaluation.
Procedures
Eight groups received medication management (MM) and either placebos, naltrexone,
acamprosate, or naltrexone + acamprosate. Half of these groups also received the CBI. A
ninth group received CBI alone with no pills in order to examine placebo effects in
secondary analyses.
Measures
Trained research assistants obtained daily report of drinking at baseline retrospectively using
the Form 90 AIR-ED (Miller, 1996; Miller and DelBoca, 1994) and with the Timeline
Follow-back interview (Sobell and Sobell, 1992, 1995) for the 16-week treatment period.
Both are comprehensive self-report measures and have good reliability and internal
consistency on summary drinking measures (Sobell and Sobell, 1992, 1995; Tonnigan et al,
1997). The dependent variable in our analysis was daily binary indicator of heavy drinking
(=1 if four or more drinks were consumed by a female, or five or more drinkers were
consumed by a male on a particular day, 0 otherwise).
The baseline characteristics were selected based on a priori expectations of their relevance to
baseline heavy drinking trajectories or as predictors of outcome (Anton and Randall, 2005;
Cisler et al., 2005). They also had complete data and meaningful statistical distributions.
Drinking behavior variables derived from the Form 90 at baseline included peak BAC
(averaged over the two heaviest drinking episodes in the 90 days prior to intake), drinks per
drinking day, percent days abstinent, percent heavy drinking days and days of abstinence
prior to randomization. Information about prior inpatient treatment or alcohol detoxification
medications, legal history, and mental health problems was obtained on the Form90; history
of alcohol withdrawal symptoms was obtained from the SCID-IV Alcohol Module (First et
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al., 1997); and current symptoms were obtained using the Clinical Withdrawal Assessment
Scale- AR (Sullivan et al., 1989) administered at intake. Other clinical assessments included
the Alcohol Dependence Scale (ADS; Skinner and Allen, 1982), the total score and the
Impulsive Drinking Subscale of the Drinker Inventory of Consequences (DrInC; Miller et
al., 1995), the total score of Obsessive Compulsive Drinking Scale (Anton et al., 1995).
Commitment to Abstinence was determined from the treatment goal question from the
Thoughts about Abstinence Scale (Hall et al., 1990). A binary variable was computed based
on the response “I want to quit using alcohol once and for all, to be totally abstinent, and
never use alcohol ever again for the rest of my life” versus all others. Participants completed
these assessments at one of the intake appointments as described in the COMBINE methods
paper (Combine Research Group, 2003).
Post-randomization drinking outcomes included percent days abstinent, percent heavy
drinking days, good clinical outcome, abstinence from heavy drinking in last two months of
the trial and continuous abstinence. Percent abstinent days and percent heavy drinking days
were based on the available drinking data from randomization through week 16. Good
Clinical Outcome was defined as abstinence or moderate drinking without problems based
on responses the Form 90 and DrInC. Moderate drinking was defined as a maximum of 11
(women) or 14 (men) drinks per week, with no more than 2 days on which more than 3
drinks (women) or 4 drinks (men) were consumed. Problems were defined as endorsing 3 or
more items on the DrInC assessing physical, social, and psychological consequences of
drinking. Abstinence from heavy drinking following a grace period has been proposed as an
outcome measure for future clinical trials because it is associated with reduced risk of
alcohol related consequences while allowing for improvements in drinking short of
abstinence (Falk et al., 2010). We included continuous abstinence as an exploratory outcome
because this was the primary outcome used in the approval of acamprosate by the FDA
based on a reanalysis of data from three European clinical trials (Kranzler and Gage, 2008).
Planned Analyses
Identification of baseline heavy drinking trajectories—We used the approach of
Nagin (1999) and Nagin and Tremblay (2001) to identify distinct trajectories of heavy
drinking patterns during the 90 days prior to randomization. The models assumed fixed
polynomial trends (linear, quadratic, cubic) over time within each trajectory. The final
models were obtained via model selection (number of trajectory classes and degree of the
polynomial trends over time) based on the Schwartz Bayesian criterion (BIC) and on having
at least 5% of subjects in each trajectory class. For the analysis we used a customized SAS
procedure (PROC TRAJ) developed by Jones et al (2001).
Based on the final trajectory models we calculated the posterior probabilities of membership
in each trajectory class for each subject. We used categorical variables of trajectory class as
response variables in the comparisons of baseline characteristics of the identified baseline
trajectories and as predictors in the analyses of drinking outcomes during treatment.
Classification accuracy was assessed using the entropy measure (Muthén, 2004) with values
between 0.9 and 1 indicating excellent classification of individuals in trajectory classes.
Assessing the association between baseline any drinking and heavy drinking
trajectories—We used bar plots to illustrate subjects’ cross-classification in trajectories of
any drinking (Gueorguieva et al., 2011) and trajectories of heavy drinking. We also
calculated weighted kappa measure of agreement between the two classifications.
Comparison of baseline heavy drinking trajectories on baseline
characteristics—We used ANOVA and chi-square tests to compare baseline
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characteristics of the subjects classified in different trajectories. We also performed
multivariate logistic regression and used backward elimination at the 0.05 level to determine
which baseline variables were most strongly associated with trajectory membership and
explained the largest proportion of variance in trajectory membership.
Predictive and moderating effects of baseline trajectories of heavy drinking
on drinking outcomes—We modeled the effect of baseline heavy drinking trajectories
and treatment (Naltrexone, Acamprosate, CBI and their interactions) on post-randomization
drinking outcomes using general linear models for continuous variables and logistic
regression models for binary outcomes.
For each drinking outcome, we performed backward elimination starting with a model with
four-way and all lower order interactions among baseline trajectories, naltrexone,
acamprosate and CBI. We then dropped non-significant interactions under the restriction
that the model was hierarchically well formulated at each step and that the sample size for
each combination of the categorical variables in the model was at least ten. All pair-wise
mean differences were tested for statistical significance and odds ratios were calculated for
the significant effects in the final models containing only main effects of baseline
trajectories.
Results
Identification of baseline heavy drinking trajectories
Similar to our results for any drinking (Gueorguieva et al., 2011), we identified five distinct
trajectories of heavy drinking prior to randomization (Figure 1). These trajectories can be
referred to as
• “T1: frequent heavy drinkers”,
• “T2: very frequent heavy drinkers”
• “T3: nearly daily heavy drinkers”
• “T4: daily heavy drinkers” and
• “T5: daily heavy drinkers stopping early”.
Entropy of the model was excellent (0.97), thus most subjects were clearly assigned to a
particular trajectory.
In all trajectories heavy drinking declined prior to randomization as required by the criteria
for study entry; however, there were differences in the chance of heavy drinking over the 90
day baseline period and the abruptness with which drinking was discontinued prior to study
entry. “T1: frequent heavy drinkers” (15.3% of the sample) had about 30% chance of
drinking heavily on a particular day. “T2: very frequent heavy drinkers” (24.7% of the
sample) had about 60% chance of drinking heavily on a particular day. “T3: nearly daily
heavy drinkers” (21.0% of the sample) had about 80% chance of drinking heavily on a
particular day. “T4: daily heavy drinkers” (25.4% of the sample) had virtually 100% chance
of drinking on a particular day and were barely able to stop drinking prior to study entry. In
contrast “T5: daily heavy drinkers stopping early” (13.5% of the sample) reduced their
heavy drinking substantially at least 15 days in advance of randomization. This might reflect
repeated attempts to achieve the required four consecutive days of abstinence prior to study
entry.
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Assessing the association between baseline any drinking and heavy drinking trajectories
Figure 2 illustrates subjects’ cross-classification in trajectories of any drinking and
trajectories of heavy drinking. In Gueorguieva et al. (2011) we identified five trajectories of
any drinking: “TA1: frequent drinkers” (40% chance of any drinking on a particular day),
“TA2: very frequent drinkers” (75% chance of drinking on a particular day), “TA3: nearly
daily drinkers” (between 80 and 90% chance of drinking on a particular day), “TA4:
consistent daily drinkers” (virtually 100% chance of drinking on a particular day and barely
able to stop drinking prior to study entry) and “TA5: daily drinkers abstaining early”
(virtually 100% chance of drinking on a particular day but stopping about 15 days prior to
randomization). The shapes of the trajectories of any drinking and heavy drinking were
similar. Most of the subjects classified in the three most intensive any drinking categories
(TA3–TA5) were also classified in the three most intensive heavy drinking categories (T3–
T5). The less frequent drinkers (in TA1 and TA2) were sometimes classified in more
intensive heavy drinking trajectories suggesting potential sample selection of individuals
with relatively infrequent but heavier drinking into the trial. In particular, most of the
subjects classified in “TA2: very frequent drinkers” were classified in “T2: very frequent
heavy drinkers” (62.1% of TA2) but a sizeable proportion were classified in “T3: nearly
daily heavy drinkers” (20.9% of TA2). All subjects classified in “TA1: frequent drinkers”
were either classified in “T1: frequent heavy drinkers” (58.7% of TA1) or in “T2: very
frequent heavy drinkers” (41% of TA1). Nevertheless, the agreement between classifications
in any drinking and heavy drinking trajectories was very good (weighted kappa = 0.70, 95%
CI: (0.67, 0.73)).
Comparison of baseline heavy drinking trajectories on baseline characteristics
Table 1 compares the five heavy drinking trajectories on summary measures of alcohol
consumption derived from the Form 90. After backward elimination only percent heavy
drinking days and days of abstinence prior to randomization were significantly associated
with trajectory membership (both p-values<0.0001). The other variables in Table 1, while
significantly associated with trajectory membership when considered one at a time, were no
longer significant in a multivariate analysis. Table 2 compares the trajectories on other
baseline characteristics found significant after backward elimination for all five trajectories
or for the comparison between “T4: daily heavy drinkers” and “T5: daily heavy drinkers
stopping early”. Although patterns of heavy drinking prior to establishing pre-treatment
abstinence were relatively similar for the two daily heavy drinking trajectories (“T4: daily
heavy drinkers” and “T5: daily heavy drinkers stopping early”, Figure 1), there were a
number of univariate differences in baseline characteristics between these two trajectories
(Tables 1 and 2). Participants in “T5: daily heavy drinkers stopping early” were more likely
to have higher ADS scores (OR=1.08, 95% CI: (1.04, 1.12)) and lower OCDS scores
(OR=0.93, 95% CI: (0.90, 0.96)). They also had more mental health problems (OR=1.81,
95% CI: (1.15, 2.85)), greater commitment to abstinence (OR=1.81, 95% CI: (1.15, 2.84))
and attendance of Alcoholics Anonymous (OR=2.45, 95% CI: (1.39, 4.30)) compared to
“T4: daily heavy drinkers”.
Predictive effects of baseline trajectories of heavy drinking on drinking outcomes
There were significant naltrexone by CBI interactions on good clinical outcome, percent
drinking days and percent heavy drinking days consistent with the original findings (p=0.01,
0.03 and 0.03 respectively). Main effects of baseline trajectory were also significant for all
outcomes (Figure 3 and Figure 4, all p-values <.01). Baseline trajectory did not interact
significantly with treatment condition.
Figure 3 shows that “T3: nearly daily heavy drinkers” (Least Squares Mean (LSM) =27.40,
SE=1.72) and “T4: consistent daily heavy drinkers” (LSM=31.85, SE=1.57) had
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significantly higher percentage of drinking days than the remaining trajectories (all p<0.005)
during the 16 week treatment period. “T4: daily heavy drinkers” also had significantly
higher percent heavy drinking days (LSM=20.34, SE=1.25) than all other trajectories (all
p<0.005) except “T3: nearly daily heavy drinkers”. “T3: nearly daily heavy drinkers” had
significantly higher percent heavy drinking days (LSM=17.90, SE=1.37) than “T1: frequent
heavy drinkers” (LSM=7.56, SE=1.61, p<.0001) and “T5: daily heavy drinkers stopping
early” (LSM=11.30, SE=1.72, p=0.003) but not compared to “T2: very frequent heavy
drinkers” (LSM=12.98, SD=1.26, p=0.009).
Figure 4 shows that compared to subjects in the three intermediate trajectories subjects in
“T5: daily heavy drinkers stopping early” had significantly higher chance for continuous
abstinence OR=1.89, 95% CI: (1.22, 2.93); OR=2.49, 95% CI: (1.55, 3.98) and OR=2.20,
95% CI: (1.41, 3.43 respectively) and abstinence from heavy drinking in the last two months
of the study (OR= 1.82, 95% CI: (1.22, 2.70); OR=2.11, 95% CI: (1.40, 3.19) and OR= 1.93,
95% CI: (1.30, 2.86) respectively). Subjects in the three intermediate trajectories (T2, T3
and T4) had significantly lower chance for good clinical outcome compared to “T1: frequent
heavy drinkers” (OR=0.40, 95% CI: (0.24, 0.68); OR=0.38, 95% CI: (0.22, 0.66) and
OR=0.29, 95% CI: (0.18, 0.49) respectively) but were not significantly different from
subjects in “T5: daily heavy drinkers stopping early” (all p>0.05). Overall, trajectories “T1:
frequent heavy drinkers” and “T5: daily drinkers stopping early” had the best outcomes and
the remaining three trajectories were ordered in severity of outcome.
Discussion
The principal finding from the current study was that pre-treatment trajectories with greater
frequency of heavy drinking were associated with poorer treatment outcome unless
accompanied by a self-imposed period of longer pre-treatment alcohol abstinence. Thus we
confirmed the hypothesis that differing patterns or trajectories of heavy drinking, during the
90 days prior to individuals’ randomization into treatment are significant predictors of
subsequent post-randomization outcomes, whether measured by parameters of drinking or
more broadly based clinical outcome. Consistent with prior work looking at any drinking
behavior during the pre-randomization period, the present analyses identified five specific
patterns of heavy drinking. There was a high degree of overlap between the five heavy
drinking trajectories with those previously found for any drinking, especially among the
more frequent heavier drinking categories. That is, individuals who drank more frequently
were also more likely to also be more frequent heavy drinkers as well.
Our results suggest that initiation of abstinence prior to treatment varied the most among
daily heavy drinkers (subjects in T4 and T5 considered together) as compared to less
frequent heavy drinkers (subjects in T1–T3). Stopping early among daily heavy drinkers
may be partially due to motivation (commitment to abstinence in the “T5: daily heavy
drinkers stopping early” was higher than in the other trajectories) but it may also be
associated with interventions used to initiate abstinence (e.g. subjects who stop early are
more likely to have received inpatient treatment).
While duration of abstinence from heavy drinking prior to treatment and frequency of heavy
drinking are by themselves important predictors of outcome (Karim et al., 2010; McLellan et
al., 1994; Moos and Moos, 2006), the value of trajectory-based analysis is that it allows
simultaneous consideration of both aspects of heavy drinking in a data-driven fashion.
Trajectory analyses capture simultaneously different aspects of drinking behavior and
present an easily interpretable graphical summary of the patterns of drinking over time. Thus
they provide advantages over summary drinking measures in identifying combinations of
features of drinking that are associated with good outcome.
Gueorguieva et al. Page 8













The better outcomes seen for daily heavy drinkers who had established a period of
abstinence are consistent with the results of Project Match, in which patients recruited into
the aftercare arm of this study had higher percentage of days abstinent and lower drinks per
drinking day than those recruited into the outpatient arm of the study (Project Match, 1998).
Like Project Match, it is difficult to determine whether the better prognosis of those with
extended pretreatment abstinence is due to baseline differences in the characteristics of
participants, prior treatment experiences, or as a function of the abstinent period.
In examining baseline characteristics, the group with longer pre-treatment abstinence had
the highest scores on a number of variables that would lead one to predict a poor prognosis
relative to other trajectory groups. In particular, its members had the highest scores on
measures related to chronicity and alcohol dependence (e.g. prior detoxification episodes,
prior treatment, alcohol dependence symptoms, and negative consequences associated with
drinking and alcohol dependence). However, in contrast to this clinical picture, or possibly
because of it, the “T5: daily heavy drinkers stopping early” also had the greatest
commitment to abstinence as a goal. This goal, as well as their greater involvement in prior
treatment, may have in fact been used by group members to attain abstinence earlier in the
period prior to randomization compared to the other group of heavy daily drinkers who did
not stop early. Stopping early is likely to be the clearest behavioral marker of this
commitment and the capacity to act on this. It is of note that the other daily heavy drinking
trajectory group (T4), while having somewhat lower levels of predictors of poor outcome
had the lowest proportion highly committed to abstinence.
The relevance of the commitment to abstinence between these two daily heavy drinking
trajectories was manifested in the differences in post-randomization drinking outcomes.
Interestingly, “daily heavy drinkers stopping early” (T5) had outcomes that were relatively
comparable to and did not differ significantly from the outcomes of the least severe baseline
trajectory “frequent heavy drinkers” (T1) while the other trajectories were associated with
significantly worse outcomes. The outcomes of these latter groups were ordered in a manner
consistent with the frequency of their pre-randomization heavy drinking, with the daily
heavy drinking trajectory members (T4) having the highest percentages of drinking and
heavy drinking and the lowest percentage of good clinical outcomes.
While there was a high correspondence of membership between individuals in the any
drinking and heavy drinking trajectories, there were some substantial differences (e.g. less
frequent drinkers were sometimes classified in more severe heavy drinking trajectories, and
some daily heavy drinkers stopping early (T5) were classified into other any drinking
trajectories which did not stop all drinking early). These two differences may explain why
baseline trajectories of any drinking significantly moderated the effects of acamprosate but
the same effect was not observed for baseline trajectories of heavy drinking. In our previous
study of patterns of the frequency of any pre-randomization drinking (Gueorguieva, 2011)
acamprosate was found to benefit those who were very frequent but not daily drinkers and
appeared not to be indicated for patients who have already achieved an extended period of
pre-treatment abstinence (e.g., >14 days). In the current analysis of heavy drinking,
however, there were no differential benefits from acamprosate. This suggests that frequent
drinking but not necessarily frequent heavy drinking predicts good outcome on acamprosate.
In addition, early discontinuation of heavy drinking is not as informative as early cessation
of all drinking for identifying individuals for whom acamprosate may not be indicated. What
appear to be more predictive of acamprosate response are patterns of drinking days
irrespective of the intensity of drinking. We were not able to test this potential explanation
of the observed differences in acamprosate effects on any and heavy drinking as only a few
combinations of trajectories of any and heavy drinking had sufficient sample sizes for
meaningful inference. Alternative approaches integrating information on the occurrence and
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amount of drinking (e.g. directly characterizing the distribution of drinking data) may
improve clinical prediction. However, this is still a very challenging issue as drinking data
are both zero inflated and right-skewed and do not satisfy any standard statistical
distribution. External validation of the results for any and heavy drinking in a different data
set can also help better understand or resolve the differences in findings.
Similarly, naltrexone condition did not interact with baseline trajectories of heavy drinking
although the interaction of naltrexone and CBI was significant on several outcomes, similar
to the primary findings of COMBINE. The potential influence of pretreatment abstinence
from heavy drinking in predicting response to naltrexone may have been attenuated because
all patients in COMBINE, like most studies of oral naltrexone, were required to have at least
4 days of abstinence prior to randomization. In contrast, pretreatment abstinence was a
predictor of stronger response to naltrexone in a trial of extended release naltrexone that did
not require pretreatment abstinence (O’Malley et al., 2007; Garbutt et al., 2005).
The present findings have implications for both research and clinical practice. From a
research perspective, data on baseline trajectory of heavy drinking could be used to inform
expected response rates for planning clinical trials based on potential inclusion criteria
related to heavy drinking. Clinically, the data indicate that individuals who are daily heavy
drinkers but who are capable of achieving and maintaining a period of abstinence from
heavy drinking have a good prognosis that exceeds what might be predicted from their
clinical history. This is particularly likely in comparison to individuals who are daily heavy
drinkers who only achieve a short duration of abstinence prior to treatment entry. The data
suggest that patients who drink at similar levels may not be similar with respect to their
capacity to respond to treatment or to modify their drinking. To better understand this
readiness for treatment, we may need to build in self-enforced pre-treatment abstinence
periods or other steps to reveal the latent capacity for change. Individuals in less favorable
trajectories may benefit from early intervention with treatments such as contingency
management (Petry et al., 2000; Carroll and Rounsaville, 2007) to promote abstinence and
to transition into more favorable trajectories.
Our study has several limitations. First, since the COMBINE Study had strict inclusion/
exclusion criteria and study procedures, the results may not generalize to more complicated
patients or to treatment provided in more general practice settings. Second, our analyses are
exporatory and limited to the 16 weeks of treatment. External validation in a different
sample is needed. Third, because of the large number of post-hoc tests, it is possible that
type I error may be inflated. Fourth, the trajectory-based analyses are predicated on the
assumption that different trajectory classes exist. If the population is homogeneous, then
spurious findings may result.
Given the lack of interactions between the baseline heavy drinking trajectories and the
pharmacological and behavioral therapies used in the COMBINE Study, the current results
do not provide guidance about patient treatment matching. The discrepancy between our
results for any drinking and heavy drinking may be due to the nature of the drinking
measures: while any drinking captures frequency of drinking, heavy drinking is more
focused on intensity of drinking. The analyses suggest that frequency of drinking is a
significant moderator of acamprosate effects, but intensity of drinking is not a significant
moderator of the effect of any treatment. Thus, for matching patients to treatments,
trajectories of any drinking may be more informative.
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Five baseline trajectories of heavy drinking. a
a Solid lines with symbols represent sample-based probabilities of drinking based on all
subjects weighted by the posterior probability of trajectory membership. Solid lines without
symbols represent model-based probabilities of drinking over time for each trajectory group.
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Cross-classification in baseline any drinking and baseline heavy drinking trajectories.
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Continuous outcomes by heavy drinking trajectories.
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Categorical outcomes by heavy drinking trajectories.
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